239 related articles for article (PubMed ID: 36565366)
1. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
2. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
3. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
Kowada A
Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
[TBL] [Abstract][Full Text] [Related]
6. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation.
Wang Z; Han W; Xue F; Zhao Y; Wu P; Chen Y; Yang C; Gu W; Jiang J
Gut; 2022 Dec; 71(12):2391-2400. PubMed ID: 35902213
[TBL] [Abstract][Full Text] [Related]
7. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
8. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
9. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
[TBL] [Abstract][Full Text] [Related]
11. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
Høgh MB; Kronborg C; Hansen JM; Schaffalitzky de Muckadell OB
Aliment Pharmacol Ther; 2019 Apr; 49(8):1013-1025. PubMed ID: 30854700
[TBL] [Abstract][Full Text] [Related]
12. Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2022 Jun; 27(3):e12886. PubMed ID: 35343031
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China.
Feng T; Zheng Z; Xu J; Cao P; Gao S; Yu X
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011621
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
17. Screening and eradication of
Liou JM; Malfertheiner P; Lee YC; Sheu BS; Sugano K; Cheng HC; Yeoh KG; Hsu PI; Goh KL; Mahachai V; Gotoda T; Chang WL; Chen MJ; Chiang TH; Chen CC; Wu CY; Leow AH; Wu JY; Wu DC; Hong TC; Lu H; Yamaoka Y; Megraud F; Chan FKL; Sung JJ; Lin JT; Graham DY; Wu MS; El-Omar EM;
Gut; 2020 Dec; 69(12):2093-2112. PubMed ID: 33004546
[TBL] [Abstract][Full Text] [Related]
18. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic screening for gastric cancer.
Dan YY; So JB; Yeoh KG
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
[TBL] [Abstract][Full Text] [Related]
20. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study.
Huang HL; Leung CY; Saito E; Katanoda K; Hur C; Kong CY; Nomura S; Shibuya K
BMC Med; 2020 Sep; 18(1):257. PubMed ID: 32921305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]